Difference between revisions of "Timeline of diphtheria"

From Timelines
Jump to: navigation, search
Line 45: Line 45:
 
| 1921 || Report || A high of 206,000 cases of diphtheria and 15,520 deaths (case-fatality ratio of 7.5%) are recorded in the United States.<ref name="Diphtheria: The Plague Among Children">{{cite web|title=Diphtheria: The Plague Among Children|url=https://www.historyofvaccines.org/timeline?timeline_categories[]=50|website=historyofvaccines.org|accessdate=8 May 2017}}</ref><ref name="Diphtheria. Symptoms and Causative Agent">{{cite web|title=Diphtheria. Symptoms and Causative Agent|url=https://www.historyofvaccines.org/content/articles/diphtheria|website=historyofvaccines.org|accessdate=10 May 2017}}</ref> || [[wikipedia:United States|United States]]
 
| 1921 || Report || A high of 206,000 cases of diphtheria and 15,520 deaths (case-fatality ratio of 7.5%) are recorded in the United States.<ref name="Diphtheria: The Plague Among Children">{{cite web|title=Diphtheria: The Plague Among Children|url=https://www.historyofvaccines.org/timeline?timeline_categories[]=50|website=historyofvaccines.org|accessdate=8 May 2017}}</ref><ref name="Diphtheria. Symptoms and Causative Agent">{{cite web|title=Diphtheria. Symptoms and Causative Agent|url=https://www.historyofvaccines.org/content/articles/diphtheria|website=historyofvaccines.org|accessdate=10 May 2017}}</ref> || [[wikipedia:United States|United States]]
 
|-
 
|-
−
| 1923 || Medical development || French biologist [[wikipedia:Gaston Ramon|Gaston Ramon]], working at [[wikipedia:Pasteur Institute|Pasteur Institute]], develops diphtheria toxoid that could later be used for a toxoid vaccination Diphtheria toxoid is licensed; prepared from inactivated bacterial toxin that has lost its toxicity but retains its antitoxin producing properties. This would be considered the first diphtheria vaccine.<ref name="Diphtheria, Tetanus (Lockjaw), and Pertussis (Whooping Cough) Cases and Deaths, and DTaP Vaccination Rates">{{cite web|title=Diphtheria, Tetanus (Lockjaw), and Pertussis (Whooping Cough) Cases and Deaths, and DTaP Vaccination Rates|url=http://vaccines.procon.org/view.additional-resource.php?resourceID=005971|website=procon.org|accessdate=10 May 2017}}</ref><ref name="Diphtheria :  Clinical Manifestations ,  Diagnosis ,  and Role  of Immunization In  Prevention"/><ref name="Vaccine Timeline"/>  ||
+
| 1923 || Scientific development || French biologist [[wikipedia:Gaston Ramon|Gaston Ramon]], working at [[wikipedia:Pasteur Institute|Pasteur Institute]], develops diphtheria toxoid that could later be used for a toxoid vaccination Diphtheria toxoid is licensed; prepared from inactivated bacterial toxin that has lost its toxicity but retains its antitoxin producing properties. This would be considered the first diphtheria vaccine.<ref name="Diphtheria, Tetanus (Lockjaw), and Pertussis (Whooping Cough) Cases and Deaths, and DTaP Vaccination Rates">{{cite web|title=Diphtheria, Tetanus (Lockjaw), and Pertussis (Whooping Cough) Cases and Deaths, and DTaP Vaccination Rates|url=http://vaccines.procon.org/view.additional-resource.php?resourceID=005971|website=procon.org|accessdate=10 May 2017}}</ref><ref name="Diphtheria :  Clinical Manifestations ,  Diagnosis ,  and Role  of Immunization In  Prevention"/><ref name="Vaccine Timeline"/>  ||
 
|-
 
|-
 
| 1924 || Scientific development || [[wikipedia:Gaston Ramon|Gaston Ramon]] discovers diphtheria and tetanus toxoid, then referred to as anatoxins.<ref>{{cite book|title=Medical Sciences - Volume I|edition=B.P. Mansourian, S.M. Mahfouz, A. Wojtezak|url=https://books.google.com.ar/books?id=Fb3VCwAAQBAJ&pg=PA124&dq=%221924%22+%22gaston+ramon%22+%22diphtheria%22&hl=en&sa=X&ved=0ahUKEwjfi-GgruPTAhVLgpAKHbY-BIIQ6AEIITAA#v=onepage&q=%221924%22%20%22gaston%20ramon%22%20%22diphtheria%22&f=false|accessdate=9 May 2017}}</ref> || [[wikipedia:France|France]]
 
| 1924 || Scientific development || [[wikipedia:Gaston Ramon|Gaston Ramon]] discovers diphtheria and tetanus toxoid, then referred to as anatoxins.<ref>{{cite book|title=Medical Sciences - Volume I|edition=B.P. Mansourian, S.M. Mahfouz, A. Wojtezak|url=https://books.google.com.ar/books?id=Fb3VCwAAQBAJ&pg=PA124&dq=%221924%22+%22gaston+ramon%22+%22diphtheria%22&hl=en&sa=X&ved=0ahUKEwjfi-GgruPTAhVLgpAKHbY-BIIQ6AEIITAA#v=onepage&q=%221924%22%20%22gaston%20ramon%22%20%22diphtheria%22&f=false|accessdate=9 May 2017}}</ref> || [[wikipedia:France|France]]

Revision as of 13:17, 10 May 2017

Year/period Key developments
19th century Diphtheria infection grows significantly late in the century to become one of the major causes of death, fuelled by the industrial revolution and increasingly crowded urban centers.[1]
1923< After the first diphtheria toxoid vaccine is developed, its subsequent widespread use would lead to a dramatic decrease of diphtheria rates worldwide.[2][3] A more than 90% decrease in number of cases globally would result later, between 1980 and 2000.[4]
Recent years Currently most diphtheria cases occur in Sub-Sharan Africa, India, and Indonesia. Globally 4,700 cases were officially reported in 2013, down from nearly 100,000 in 1980.[4]

Full timeline

Year/period Type of event Event Present time geographical location
5th century BC Scientific development Diphtheria is first described by Greek physician Hippocrates.[5][6] Greece
1600s Scientific development Medical reports of a "deadly" strangulation disease first appear early in the century, and emerges as a greater threat with the growth of urbanizations.[1][6]
1613 Epidemic Diphtheria epidemic in Spain causes the year to be named "El año de los Garotillos" ("year of strangulations"), due to the many deaths caused by diphtheria suffocation.[7] Spain
1826 Scientific development French physician Pierre Bretonneau gives diphtheria its official name diphtérite, derived from the Greek word for "leather" or "hide", which describes the pseudomembrane in the throat of the victims.[1][8][7]
1856 Epidemic San Francisco doctor Victor Fourgeaud describes an epidemic of diphtheria in California.[4] United States
1883 Scientific development Swiss pathologist Edwin Klebs first observes the diphtheria bacterium corynebacterium diphtheriae in diphtheritic membranes.[6][7]
1884 Scientific development German bacteriologist Friedrich Loeffler first grows diphtheria bacterium corynebacterium diphtheriae in pure culture.[9][2][6][7] Germany
1888 Scientific development French physicians Pierre Paul Émile Roux and Alexandre Yersin, working at Pasteur Institute, discover the diphtheria toxin.[10][7] France
1890 Medical development German physiologist Emil von Behring develops the first effective therapeutic serum against diphtheria. In 1901 Von Bering would be awarded the first Nobel Prize in Physiology or Medicine for this work.[11][12] Germany
1891 Medical development The first successful therapeutic serum treatment of a child suffering from diphtheria is performed.[11]
1894 Medical development The production and marketing of the diphtheria therapeutic serum begins in Germany.[11] Germany
1901 Medical development Emil von Behring, for the first time, uses a diphtheria innoculation of bacteria with reduced virulence, hoping with this active immunization to help the body also produce antitoxins.[11] Germany
1905 Medical development Franklin Royer publishes a paper urging timely treatment for diphtheria and adequate doses of antitoxin.[4]
1913 Medical development Emil von Behring publishes his diphtheria protective agent, T.A. (Toxin-Antitoxin), which contains a mixture of diphtheria toxin and therapeutic serum antitoxin. Designed to provide long-term protection, the new drug would further be tested at various clinics and proven to be non-harmful and effective.[11] Germany
1921 Report A high of 206,000 cases of diphtheria and 15,520 deaths (case-fatality ratio of 7.5%) are recorded in the United States.[13][14] United States
1923 Scientific development French biologist Gaston Ramon, working at Pasteur Institute, develops diphtheria toxoid that could later be used for a toxoid vaccination Diphtheria toxoid is licensed; prepared from inactivated bacterial toxin that has lost its toxicity but retains its antitoxin producing properties. This would be considered the first diphtheria vaccine.[15][4][12]
1924 Scientific development Gaston Ramon discovers diphtheria and tetanus toxoid, then referred to as anatoxins.[16] France
1926 Medical development British immunologist Alexander Glenny, working at Wellcome Research Laboratories, develops the adjuvant (the substance that enhances the body's immune response to an antigen) for the toxoid vaccine by increasing the effectiveness of diphtheria toxoid when treating it with aluminum salts.[4][15] United Kingdom (London)
1947 Medical development Combination diphtheria and tetanus toxoids for pediatric use is first licensed in the United States.[12] United States
1953 Medical development Tetanus and diphtheria toxoids (adult formulation) are first licensed in the United States, after the concentration of diphtheria toxoid is reduced.[12] United States
1964 Policy World Health Organization recommendations for the production and quality control of diphtheria vaccines are first formulated.[17]
1971 Epidemic Seattle experiences the last major diphtheria outbreak in the United States.[18] United States
1974 Program launch Diphtheria toxoid combined with tetanus and pertussis vaccines (DTP) is included in the newly incepted WHO Expanded Programme on Immunization.[17]
1974 Epidemic Diphtheria epidemic breaks out in Lisbon. 500 persons are involved, and about 40 deaths are recorded.[9] Portugal
1982 Epidemic 5 deaths are recorded in Germany during a diphtheria outbreak.[9] Germany
1990-1998 Epidemic Massive diphtheria epidemic breaks out in the ex-Soviet Union. Starting in Russia, the outbreak reaches the Newly Independent States in 1991.[19][18]
1996 Medical development Lederle Laboratories licenses diphtheria and tetanus toxoids and acellular pertussis vaccine Acel-Imune, for use as the first through fifth doses in the series.[12]
1997 Medical development British pharmaceutical company SmithKline Beecham licenses Infanrix (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed), for the first four doses of the series.[12]
1998 Medical development North American Vaccine Inc licenses Certiva (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed), for boosting immunization of infants and children.[12]
1999 Medical development Connaught Laboratories licenses diphtheria and tetanus toxoids and acellular pertussis vaccine Tripedia.[12]
2002 Medical development British pharmaceutical GlaxoSmithKline licenses Pediarix, a vaccine combining diphtheria, tetanus, acellular pertussis, inactivated polio, and hepatitis B antigens.[12]
2002 Medical development Aventis Pasteur licenses diphtheria and tetanus toxoids and acellular pertussis vaccine Daptacel.[12]
2004 Medical development Aventis Pasteur licenses vaccine Decavac, indicated for active immunization against tetanus and diphtheria.[12][20]
2005 Medical development Sanofi Pasteur licenses Menactra, the first meningococcal polysaccharide (Serogroups A, C, Y and W-135) diphtheria toxoid conjugate vaccine. This would be the first immunogenic meningococcal vaccine indicated for children younger than 2 years of age.[12]
2007 Report 4,190 cases of diphtheria are reported globally.[13]
2011 Medical development United States Food and Drug Administration approves Boostrix (developed by GlaxoSmithKline) to prevent tetanus, diphtheria, and pertussis in older people.[12] United States

See also

  1. ↑ 1.0 1.1 1.2 "The strangler". museumofhealthcare.ca. Retrieved 9 May 2017. 
  2. ↑ 2.0 2.1 "Diphtheria Facts". emedicinehealth.com. Retrieved 9 May 2017. 
  3. ↑ "Clinicians". cdc.gov. Retrieved 10 May 2017. 
  4. ↑ 4.0 4.1 4.2 4.3 4.4 4.5 "Diphtheria : Clinical Manifestations , Diagnosis , and Role of Immunization In Prevention" (PDF). iosrjournals.org. Retrieved 10 May 2017. 
  5. ↑ "Diphtheria". medscape.com. Retrieved 8 May 2017. 
  6. ↑ 6.0 6.1 6.2 6.3 "Corynebacterium diphtheriae" (PDF). cdc.gov. Retrieved 10 May 2017. 
  7. ↑ 7.0 7.1 7.2 7.3 7.4 Current Developments in Biotechnology and Bioengineering: Human and Animal Health Applications (Vanete Thomaz Soccol, Ashok Pandey, Rodrigo R. Resende ed.). Retrieved 10 May 2017. 
  8. ↑ "Pierre Bretonneau". historyofvaccines.org. Retrieved 9 May 2017. 
  9. ↑ 9.0 9.1 9.2 KWANTES, W. "Diphtheria in Europe" (PDF). nih.gov. Retrieved 8 May 2017. 
  10. ↑ Ladant, Daniel; Alouf, Joseph E.; Popoff, Michel R. The Comprehensive Sourcebook of Bacterial Protein Toxins. 
  11. ↑ 11.0 11.1 11.2 11.3 11.4 "Emil von Behring: The Founder of Serum Therapy". nobelprize.org. Retrieved 9 May 2017. 
  12. ↑ 12.00 12.01 12.02 12.03 12.04 12.05 12.06 12.07 12.08 12.09 12.10 12.11 12.12 "Vaccine Timeline". immunize.org. Retrieved 8 May 2017. 
  13. ↑ 13.0 13.1 "Diphtheria: The Plague Among Children". historyofvaccines.org. Retrieved 8 May 2017. 
  14. ↑ "Diphtheria. Symptoms and Causative Agent". historyofvaccines.org. Retrieved 10 May 2017. 
  15. ↑ 15.0 15.1 "Diphtheria, Tetanus (Lockjaw), and Pertussis (Whooping Cough) Cases and Deaths, and DTaP Vaccination Rates". procon.org. Retrieved 10 May 2017. 
  16. ↑ Medical Sciences - Volume I (B.P. Mansourian, S.M. Mahfouz, A. Wojtezak ed.). Retrieved 9 May 2017. 
  17. ↑ 17.0 17.1 "Diphtheria". who.int. Retrieved 10 May 2017. 
  18. ↑ 18.0 18.1 "History in Focus: Diphtheria Epidemic". hampton.lib.nh.us. Retrieved 10 May 2017. 
  19. ↑ "Diphtheria Outbreak -- Russian Federation, 1990-1993". cdc.gov. Retrieved 10 May 2017. 
  20. ↑ "HIGHLIGHTS OF PRESCRIBING INFORMATION" (PDF). vaccineshoppe.com. Retrieved 8 May 2017. 
Retrieved from "http://timelines.issarice.com/index.php?title=Timeline_of_diphtheria&oldid=13753"